drugset / Trial / NCT04152980

Pentoxifylline Dose Optimization in Neonatal Sepsis

NCT04152980

Phase 3 Completed 30 enrolled Erasmus Medical Center
Non-randomizedSequentialOpen-labelTreatment

Summary

Sepsis is a very important cause of death and morbidity in preterm infants. There are strong indications that preterm neonates with sepsis could benefit, next to antibiotics, from treatment with pentoxifylline (PTX). Knowledge about optimal dosing is however limited. This study is a dose optimization study using a step-up and step-down model. In order to find the optimal dose, the infusion of pentoxifylline in different dosages will be studied, next to antibiotics with 3 patients per dosage. After the dose optimization study an additional cohort of 10 patients will be treated with the found dosage as a validation of the dose.

Timeline

Start
2020-01-12
Primary completion
2022-10-31
Completion
2022-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Pentoxifylline Small molecule 2.5 mg/kg Intravenous
Subject Pentoxifylline Small molecule 5 mg/kg Intravenous

Indications